| MeSH term | MeSH ID | Detail |
|---|---|---|
| Scorpion Stings | D065008 | 1 associated lipids |
| Drug-Related Side Effects and Adverse Reactions | D064420 | 3 associated lipids |
| Retrognathia | D063173 | 1 associated lipids |
| End Stage Liver Disease | D058625 | 1 associated lipids |
| Candidiasis, Invasive | D058365 | 2 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Thrombotic Microangiopathies | D057049 | 1 associated lipids |
| Central Serous Chorioretinopathy | D056833 | 1 associated lipids |
| Leukoencephalopathies | D056784 | 3 associated lipids |
| Netherton Syndrome | D056770 | 1 associated lipids |
| Latent Tuberculosis | D055985 | 1 associated lipids |
| Invasive Pulmonary Aspergillosis | D055744 | 1 associated lipids |
| Keratosis, Actinic | D055623 | 3 associated lipids |
| Multiple Pulmonary Nodules | D055613 | 2 associated lipids |
| Pancreatitis, Graft | D055589 | 1 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
| Primary Graft Dysfunction | D055031 | 1 associated lipids |
| Idiopathic Interstitial Pneumonias | D054988 | 1 associated lipids |
| Dendritic Cell Sarcoma, Interdigitating | D054739 | 1 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Posterior Leukoencephalopathy Syndrome | D054038 | 1 associated lipids |
| Dysuria | D053159 | 1 associated lipids |
| Nocturia | D053158 | 1 associated lipids |
| Delayed Graft Function | D051799 | 2 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Lymphohistiocytosis, Hemophagocytic | D051359 | 1 associated lipids |
| Granulomatosis, Orofacial | D051261 | 2 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Dyslipidemias | D050171 | 7 associated lipids |
| Diabetes Complications | D048909 | 4 associated lipids |
| Hepatic Insufficiency | D048550 | 1 associated lipids |
| Colitis, Collagenous | D046729 | 1 associated lipids |
| Protoporphyria, Erythropoietic | D046351 | 1 associated lipids |
| Coproporphyria, Hereditary | D046349 | 1 associated lipids |
| Ileus | D045823 | 3 associated lipids |
| Intestinal Volvulus | D045822 | 1 associated lipids |
| Cholecystolithiasis | D041761 | 2 associated lipids |
| Mastocytosis, Cutaneous | D034701 | 1 associated lipids |
| Hypoalbuminemia | D034141 | 1 associated lipids |
| Hyperuricemia | D033461 | 4 associated lipids |
| Papillomavirus Infections | D030361 | 4 associated lipids |
| Denys-Drash Syndrome | D030321 | 1 associated lipids |
| Pulmonary Disease, Chronic Obstructive | D029424 | 16 associated lipids |
| Polyomavirus Infections | D027601 | 1 associated lipids |
| Coronary Stenosis | D023921 | 6 associated lipids |
| Lacerations | D022125 | 1 associated lipids |
| Brachial Plexus Neuritis | D020968 | 2 associated lipids |
| Neuroaspergillosis | D020953 | 2 associated lipids |
| Hypoxia-Ischemia, Brain | D020925 | 22 associated lipids |
| Central Nervous System Viral Diseases | D020805 | 1 associated lipids |
| Intracranial Thrombosis | D020767 | 2 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
| Nervous System Autoimmune Disease, Experimental | D020721 | 3 associated lipids |
| Stroke | D020521 | 32 associated lipids |
| Brain Infarction | D020520 | 17 associated lipids |
| Peroneal Neuropathies | D020427 | 1 associated lipids |
| Sciatic Neuropathy | D020426 | 13 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Paraneoplastic Syndromes, Nervous System | D020361 | 1 associated lipids |
| Hypertensive Encephalopathy | D020343 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Ventricular Remodeling | D020257 | 28 associated lipids |
| Infarction, Middle Cerebral Artery | D020244 | 35 associated lipids |
| Optic Nerve Injuries | D020221 | 4 associated lipids |
| Facial Nerve Injuries | D020220 | 1 associated lipids |
| Trauma, Nervous System | D020196 | 2 associated lipids |
| Nocturnal Myoclonus Syndrome | D020189 | 1 associated lipids |
| Sleep Apnea, Central | D020182 | 1 associated lipids |
| Citrullinemia | D020159 | 1 associated lipids |
| Hepatopulmonary Syndrome | D020065 | 1 associated lipids |
| Epstein-Barr Virus Infections | D020031 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Miller Fisher Syndrome | D019846 | 1 associated lipids |
| Hepatitis C, Chronic | D019698 | 12 associated lipids |
| Hepatitis B, Chronic | D019694 | 4 associated lipids |
| Hepatitis, Autoimmune | D019693 | 1 associated lipids |
| Neurodegenerative Diseases | D019636 | 32 associated lipids |
| Intracranial Hypertension | D019586 | 4 associated lipids |
| Dermatitis, Perioral | D019557 | 4 associated lipids |
| Pouchitis | D019449 | 3 associated lipids |
| Endotoxemia | D019446 | 27 associated lipids |
| Oral Ulcer | D019226 | 1 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Fasciitis, Necrotizing | D019115 | 1 associated lipids |
| Postoperative Hemorrhage | D019106 | 7 associated lipids |
| Multiple Endocrine Neoplasia Type 2a | D018813 | 1 associated lipids |
| Anemia, Iron-Deficiency | D018798 | 6 associated lipids |
| Encephalitis, Viral | D018792 | 3 associated lipids |
| Hypoplastic Left Heart Syndrome | D018636 | 1 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Lichen Sclerosus et Atrophicus | D018459 | 2 associated lipids |
| Vasculitis, Leukocytoclastic, Cutaneous | D018366 | 5 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Angiofibroma | D018322 | 2 associated lipids |
| Cervical Intraepithelial Neoplasia | D018290 | 1 associated lipids |
| Seminoma | D018239 | 2 associated lipids |
| Smooth Muscle Tumor | D018235 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Rosen HR et al. | Significance of early aminotransferase elevation after liver transplantation. | 1998 | Transplantation | pmid:9448146 |
| Frassetto LA et al. | Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients. | 2014 | Transplantation | pmid:24389906 |
| Fung JJ | Tacrolimus and transplantation: a decade in review. | 2004 | Transplantation | pmid:15201685 |
| Kee TY et al. | Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. | 2006 | Transplantation | pmid:16861939 |
| Pascual J et al. | Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. | 2006 | Transplantation | pmid:16861942 |
| Sawabe T et al. | Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. | 1997 | Transplantation | pmid:9233725 |
| Johnson MC et al. | QT prolongation and Torsades de Pointes after administration of FK506. | 1992 | Transplantation | pmid:1373538 |
| Kim YI et al. | Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. | 1992 | Transplantation | pmid:1373539 |
| van Hooff JP et al. | A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. | 2003 | Transplantation | pmid:12829890 |
| Heffron TG et al. | Pediatric liver transplantation with daclizumab induction. | 2003 | Transplantation | pmid:12829908 |
| Stegall MD et al. | Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. | 1997 | Transplantation | pmid:9422416 |
| Bierer BE et al. | Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. | 1990 | Transplantation | pmid:1694317 |
| Shihab FS et al. | Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. | 1997 | Transplantation | pmid:9422427 |
| Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
| Donnadieu B et al. | Central retinal vein occlusion-associated tacrolimus after liver transplantation. | 2014 | Transplantation | pmid:25955343 |
| Oz HS et al. | Provocative effects of the immunosuppressants rapamycin, tacrolimus, and dexamethasone on pneumonitis in contrast to the anti- pneumonitis effects of mycophenolate mofetil. | 2001 | Transplantation | pmid:11685124 |
| Staatz CE et al. | Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. | 2001 | Transplantation | pmid:11579300 |
| Vacher-Coponat H et al. | Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. | 2006 | Transplantation | pmid:16926601 |
| Selzner N et al. | Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. | 2001 | Transplantation | pmid:11579301 |
| Fisher NC et al. | Chronic renal failure following liver transplantation: a retrospective analysis. | 1998 | Transplantation | pmid:9679823 |
| Ciancio G et al. | Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. | 2011 | Transplantation | pmid:22027927 |
| Newell KA et al. | Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. | 1997 | Transplantation | pmid:9381541 |
| Mor E et al. | Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. | 1992 | Transplantation | pmid:1279849 |
| Hirano Y et al. | The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. | 1992 | Transplantation | pmid:1279850 |
| Hilbrands R et al. | Predictive factors of allosensitization after immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts. | 2013 | Transplantation | pmid:23857001 |
| Kihm LP et al. | Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography. | 2012 | Transplantation | pmid:22470107 |
| Hoogtanders K et al. | Dried blood spot measurement of tacrolimus is promising for patient monitoring. | 2007 | Transplantation | pmid:17264824 |
| Ahuja M et al. | Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis. | 2001 | Transplantation | pmid:11349723 |
| Tanaka M et al. | Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. | 1996 | Transplantation | pmid:8830837 |
| Opelz G | Comparison of FK506 and cyclosporine. | 1996 | Transplantation | pmid:8830844 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
| Ekberg H et al. | The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. | 2009 | Transplantation | pmid:19424036 |
| Jain A et al. | Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. | 2001 | Transplantation | pmid:11374410 |
| Cherikh WS et al. | Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. | 2003 | Transplantation | pmid:14627905 |
| Neumann UP et al. | Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. | 2001 | Transplantation | pmid:11374419 |
| Rajesh KG et al. | Mitochondrial permeability transition-pore inhibition enhances functional recovery after long-time hypothermic heart preservation. | 2003 | Transplantation | pmid:14627909 |
| Vignali D et al. | IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody. | 2016 | Transplantation | pmid:27306531 |
| Chakrabarti P et al. | Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. | 2000 | Transplantation | pmid:11003353 |
| Arroyo Hornero R et al. | CD45RA Distinguishes CD4+CD25+CD127-/low TSDR Demethylated Regulatory T Cell Subpopulations With Differential Stability and Susceptibility to Tacrolimus-Mediated Inhibition of Suppression. | 2017 | Transplantation | pmid:28118317 |
| Ochiai T et al. | Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. | 1989 | Transplantation | pmid:2474209 |
| Tan HP et al. | Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. | 2008 | Transplantation | pmid:19104412 |
| Muraki T et al. | Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. | 1995 | Transplantation | pmid:7544038 |
| Yamani MH et al. | The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. | 2000 | Transplantation | pmid:10868634 |
| Blakolmer K et al. | Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. | 2000 | Transplantation | pmid:10868635 |
| Verleden GM et al. | Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. | 2002 | Transplantation | pmid:12131703 |
| Miller J et al. | Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. | 2000 | Transplantation | pmid:10755543 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. | 2004 | Transplantation | pmid:14742989 |
| Bendahan J et al. | The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. | 1994 | Transplantation | pmid:7511255 |
| Dieterle CD et al. | Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. | 2004 | Transplantation | pmid:15239622 |
| Ekberg H et al. | Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. | 2011 | Transplantation | pmid:21562449 |